

12 January 2015

Antisense Therapeutics to present at Biotech Showcase™ 2015

Antisense Therapeutics (ANP) is pleased to advise that Mark Diamond, ANP's CEO and Managing Director, will present at the Biotech Showcase conference on January 13 at 4pm in San Francisco, CA.

The presentation will be available as a webcast two hours after the presentation time, approximately 1pm, January 14, Australian Eastern Day Time. It will be available for 90 days and be accessed on the link below:

<http://edge.media-server.com/m/p/9uewc4i6>

Biotech Showcase is an investor and partnering conference held during the course of one of the industry's largest annual healthcare investor conferences (33rd Annual J.P. Morgan Conference). Now in its seventh year, Biotech Showcase is expected to attract upwards of 1,700 attendees.

Investors and biopharmaceutical executives from around the world gather in San Francisco during the week commencing Monday 12th January, 2015. This is a significant opportunity for ANP to present to and meet with US-based investors and prospective pharmaceutical partners.

Contact Information:

Website: www.antisense.com.au

Managing Director: Mark Diamond +61 (0)3 9827 8999

USA Investor/Media: Joshua Drumm +(1) 212 375 2664; jdrumm@tiberend.com

Australian Investor/Media: Annabel Murphy +61 (0)2 9237 2800; amurphy@buchanwe.com.au

Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. ANP has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals Inc., world leaders in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS), ATL1103 drug designed to block GHR production which in a Phase II clinical trial, successfully reduced blood IGF-I levels in patients with the growth disorder acromegaly, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.